SPAG9 expression is increased in human prostate cancer and promotes cell motility, invasion and angiogenesis in vitro Corrigendum in /10.3892/or.2022.8314

Chen,Feifei; Lu,Zheng; Deng,Junpeng; Han,Xuechao; Bai,Jin; Liu,Qinghua; Xi,Yaguang; Zheng,Junnian

doi:10.3892/or.2014.3539

SPAG9 expression is increased in human prostate cancer and promotes cell motility, invasion and angiogenesis in vitro

Corrigendum in: /10.3892/or.2022.8314

Authors:
- Feifei Chen
- Zheng Lu
- Junpeng Deng
- Xuechao Han
- Jin Bai
- Qinghua Liu
- Yaguang Xi
- Junnian Zheng
View Affiliations

Affiliations: Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou, Jiangsu, P.R. China, School of Pathology, Xuzhou Medical College, Xuzhou, Jiangsu, P.R. China
Published online on: October 10, 2014 https://doi.org/10.3892/or.2014.3539
Pages: 2533-2540

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sperm-associated antigen 9 (SPAG9) is a recently characterized oncoprotein involved in the progression of several human malignancies. To elucidate the role of SPAG9 in the development of human prostate cancer (PCa), tissue microarray (TMA) and immunohistochemistry were used to detect the clinical relevance of SPAG9 in PCa tissues. We found that SPAG9 expression was increased in the PCa tissues when compared with the level in the tumor adjacent normal prostate tissues, and increased SPAG9 staining was significantly correlated with TNM stage and tumor grade. We also examined prostate cancer cell motility, invasion and angiogenesis ability following reduced SPAG9 expression by siRNA. Our data showed that knockdown of SPAG9 in prostate cancer cell lines inhibited cell motility and invasion due to the inactivation of metalloproteinase-2 (MMP‑2)/MMP-9 by upregulation of tissue inhibitor of metalloproteinase-1 (TIMP-1)/TIMP-2. Furthermore, downregulation of vascular endothelial growth factor (VEGF) secretion greatly contributed to the reduced ability of angiogenesis. Our data indicate that SPAG9 expression is significantly increased in PCa and it may be involved in the process of prostate cancer cell motility, migration and angiogenesis.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
2	Ohlmann CH, Siemer S and Stöckle M: Resection of metastases from prostate cancer. Urologe A. 51:363–367. 2012.(In German).
3	Saleem M, Adhami VM, Zhong W, et al: A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev. 15:217–227. 2006. View Article : Google Scholar
4	Simpson AJ, Caballero OL, Jungbluth A, Chen YT and Old LJ: Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 5:615–625. 2005. View Article : Google Scholar : PubMed/NCBI
5	Zendman AJ, Ruiter DJ and Van Muijen GN: Cancer/testis-associated genes: identification, expression profile, and putative function. J Cell Physiol. 194:272–288. 2003. View Article : Google Scholar : PubMed/NCBI
6	Garg M, Chaurasiya D, Rana R, et al: Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer. Clin Cancer Res. 13:1421–1428. 2007. View Article : Google Scholar : PubMed/NCBI
7	Garg M, Kanojia D, Suri S and Suri A: Small interfering RNA-mediated downregulation of SPAG9 inhibits cervical tumor growth. Cancer. 115:5688–5699. 2009. View Article : Google Scholar : PubMed/NCBI
8	Kanojia D, Garg M, Gupta S, Gupta A and Suri A: Sperm-associated antigen 9, a novel biomarker for early detection of breast cancer. Cancer Epidemiol Biomarkers Prev. 18:630–639. 2009. View Article : Google Scholar : PubMed/NCBI
9	Garg M, Kanojia D, Salhan S, et al: Sperm-associated antigen 9 is a biomarker for early cervical carcinoma. Cancer. 115:2671–2683. 2009. View Article : Google Scholar : PubMed/NCBI
10	Chung MS, Lee SH, Lee DH and Chung BH: Evaluation of the 7th American Joint Committee on Cancer TNM staging system for prostate cancer in point of classification of bladder neck invasion. Jpn J Clin Oncol. 43:184–188. 2013. View Article : Google Scholar : PubMed/NCBI
11	Van der Kwast T, Bubendorf L, Mazerolles C, et al: Guidelines on processing and reporting of prostate biopsies: the 2013 update of the Pathology Committee of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Virchows Arch. 463:367–377. 2013.PubMed/NCBI
12	Chen F, Wang M, Bai J, et al: Role of RUNX3 in suppressing metastasis and angiogenesis of human prostate cancer. PLoS One. 9:e869172014. View Article : Google Scholar : PubMed/NCBI
13	Mei PJ, Bai J, Liu H, et al: RUNX3 expression is lost in glioma and its restoration causes drastic suppression of tumor invasion and migration. J Cancer Res Clin Oncol. 137:1823–1830. 2011. View Article : Google Scholar : PubMed/NCBI
14	Chen F, Bai J, Li W, et al: RUNX3 suppresses migration, invasion and angiogenesis of human renal cell carcinoma. PLoS One. 8:e562412013. View Article : Google Scholar : PubMed/NCBI
15	Jagadish N, Rana R, Selvi R, et al: Characterization of a novel human sperm-associated antigen 9 (SPAG9) having structural homology with c-Jun N-terminal kinase-interacting protein. Biochem J. 389:73–82. 2005. View Article : Google Scholar : PubMed/NCBI
16	Burks DJ, Carballada R, Moore HD and Saling PM: Interaction of a tyrosine kinase from human sperm with the zona pellucida at fertilization. Science. 269:83–86. 1995. View Article : Google Scholar : PubMed/NCBI
17	Luconi M, Krausz C, Forti G and Baldi E: Extracellular calcium negatively modulates tyrosine phosphorylation and tyrosine kinase activity during capacitation of human spermatozoa. Biol Reprod. 55:207–216. 1996. View Article : Google Scholar
18	Garg M, Kanojia D, Khosla A, et al: Sperm-associated antigen 9 is associated with tumor growth, migration, and invasion in renal cell carcinoma. Cancer Res. 68:8240–8248. 2008. View Article : Google Scholar : PubMed/NCBI
19	Mocarska A, Staroslawska E, Iwonna ZC, et al: Diagnostic imaging of the prostate cancer. Pol Merkur Lekarski. 33:357–363. 2012.(In Polish).
20	Sfoungaristos S and Perimenis P: Clinical and pathological variables that predict changes in tumour grade after radical prostatectomy in patients with prostate cancer. Can Urol Assoc J. 7:E93–E97. 2013. View Article : Google Scholar : PubMed/NCBI
21	Hynes RO: Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants - or both? Cell. 113:821–823. 2003. View Article : Google Scholar : PubMed/NCBI
22	Halbersztadt A, Halon A, Pajak J, Robaczynski J, Rabczynski J and St Gabrys M: The role of matrix metalloproteinases in tumor invasion and metastasis. Ginekol Pol. 77:63–71. 2006.(In Polish).
23	Zhang XY, Hong BF, Chen GF, Lu YL and Zhong M: Significance of MMP2 and MMP9 expression in prostate cancer. Zhonghua Nan Ke Xue. 11:359–361. 3642005.(In Chinese).
24	Jinga DC, Blidaru A, Condrea I, et al: MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. J Cell Mol Med. 10:499–510. 2006. View Article : Google Scholar : PubMed/NCBI
25	Giannelli G, Erriquez R, Fransvea E, et al: Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients. Int J Cancer. 109:782–785. 2004. View Article : Google Scholar : PubMed/NCBI
26	Chen Y, Wei X, Guo C, et al: Runx3 suppresses gastric cancer metastasis through inactivation of MMP9 by upregulation of TIMP-1. Int J Cancer. 129:1586–1598. 2011. View Article : Google Scholar : PubMed/NCBI
27	Yi F, Ni W, Liu W, et al: SPAG9 is overexpressed in human astro-cytoma and promotes cell proliferation and invasion. Tumour Biol. 34:2849–2855. 2013. View Article : Google Scholar : PubMed/NCBI
28	Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
29	Ellis LM, Rosen L and Gordon MS: Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies. Clin Adv Hematol Oncol. 4:1–10. 2006.PubMed/NCBI
30	Shi Q, Le X, Abbruzzese JL, et al: Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res. 61:4143–4154. 2001.PubMed/NCBI
31	Cao Y, Guangqi E, Wang E, et al: VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression. Cancer Res. 72:3912–3918. 2012. View Article : Google Scholar : PubMed/NCBI
32	Xie K, Wei D, Shi Q and Huang S: Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev. 15:297–324. 2004. View Article : Google Scholar : PubMed/NCBI
33	Pal S, Datta K and Mukhopadhyay D: Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res. 61:6952–6957. 2001.PubMed/NCBI
34	Guma M, Rius J, Duong-Polk KX, Haddad GG, Lindsey JD and Karin M: Genetic and pharmacological inhibition of JNK ameliorates hypoxia-induced retinopathy through interference with VEGF expression. Proc Natl Acad Sci USA. 106:8760–8765. 2009. View Article : Google Scholar : PubMed/NCBI